Team2022-11-15T13:25:53-05:00

Team

Executive leadership
Board members
Our partners
SubheadEXECUTIVE LEADERSHIP
ANTHONY P. MACK, MBA2022-05-23T19:37:04-04:00
Mack headshot

Chairman + CEO

Anthony P. Mack is an entrepreneur who has founded three successful pharmaceutical companies, served on executive boards and has more than 35 years of experience in the industry including 10 years in finance. Prior to founding and taking Virpax Pharmaceuticals public (Nasdaq: VRPX), Mr. Mack founded Scilex Pharmaceuticals and served as President, CEO and Director until February 2018. Scilex was sold to a publicly traded company. Mr. Mack founded his first pharmaceutical company, ProSolus Pharmaceuticals, in 2009 where he served as President and Director before selling the company to Mission Pharmacal in 2015. As a key executive in the pharmaceutical industry, Mr. Mack has overseen global strategies to advance business development, product development, market research, regulatory positioning, marketing and commercialization. Prior to his pharmaceutical career, Mr. Mack worked in the financial sector, starting as a Series 7 broker dealer then a Series 24 licensed Principal, allowing him to supervise and manage brokers at affiliated branches. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

JEFFREY GUDIN, MD2021-04-21T19:00:49-04:00

EVP, Chief Medical Officer

Jeffrey Gudin, MD, is co-founder and Executive Vice President at Virpax. Dr. Gudin completed both an anesthesiology residency and pain management fellowship at Yale University School of Medicine, and has been active in the pain management space as a clinician, consultant and researcher for more than 25 years. He is  Board Certified in Pain Medicine, Anesthesiology, Addiction Medicine and Hospice and Palliative Medicine. Dr. Gudin is on faculty at the University of Miami Miller School of Medicine in the Department of Anesthesiology, Perioperative Medicine and Pain Management. He has assisted in the development and marketing of numerous analgesics, and is currently principal investigator on an analgesic project awarded a grant through the National Center for Advancement of Translational Sciences at the NIH. He has presented at numerous national and international pain congresses, and has dedicated his career towards risk management and the development of safer, more effective pain medications.

GERALD W. BRUCE2021-07-30T14:06:38-04:00

Gerald W. Bruce has spent over 30 years, including 20 years in senior leadership roles, in the Pharmaceutical and Medical Nutrition industry. He started his career at Johnson and Johnson where he was an award-winning sales representative and held leadership positions of increasing responsibility in sales and marketing ending with his role as Group Product Director of Analgesics. He then served as Vice President of Sales at Bristol-Myers Squibb where he led the Cardiovascular and Metabolic sales force responsible for over $1.2 Billion in sales. He later served as Vice President of Managed Markets where he led the team responsible for the development and implementation of the reimbursement strategy for the Bristol-Myers Squibb $7 billion US portfolio. Mr. Bruce went on to become the Senior Vice President of Commercial Operations at NitroMed where he was responsible for building the commercial strategy and led the team responsible for the development and implementation of the commercial plan for the start-up company’s first product for the treatment of Heart Failure. He also spent close to ten years in the Medical Nutrition industry where he was Vice President of Sales for Nutricia North America, Danone Medical Nutrition Division. Mr. Bruce currently serves as Chairman of the Board of Trustees for Lincoln University and serves on the executive committee of the Board for the National Sales Network. He received his bachelor’s degree in Business Administration from Lincoln University and a master’s degree in Leadership from the McDonough School of Business at Georgetown University.

CHRISTOPHER M. CHIPMAN, CPA2021-04-21T18:56:31-04:00

Chief Financial Officer

Christopher M. Chipman has been a managing member of Chipman & Chipman, LLC, since November 2000, a consulting firm that assists public companies with the preparation of periodic reports required to be filed with the Securities and Exchange Commission and compliance with Section 404 of the Sarbanes Oxley Act of 2002. The firm also provides outsourced financial resources to clients assisting in financial reporting, forecasting and accounting services for a variety of clients including pharmaceutical, agriculture and construction industries. Mr. Chipman is a CPA and was Chief Financial Officer and Secretary of Capital Gold Corporation from 2006 to June 2011. Capital Gold Corporation was a publicly-held gold production and exploration company, until its acquisition by AuRico Gold, Inc. (formerly, Gammon Gold). During his tenure, Capital Gold Corporation’s market capitalization increased from $40 million to $420 million. In addition, Capital Gold experienced an increase in proven and probable reserves in excess of 200%. Mr. Chipman successfully negotiated and facilitated the $420 million sale of Capital Gold Corporation to AuRico Gold representing a 67% premium over its market price to its shareholders. Additionally, Mr. Chipman oversaw the acquisition and integration into Capital Gold Corporation of Nayarit Gold in 2010, a $48 million Canadian advanced exploration company, including involvement in its valuation accounting and application of the purchase price allocation for the transaction.  From 1996 to 1998, he was a senior accountant with the accounting firm of Grant Thornton LLP; a Senior Financial Analyst for GlaxoSmithKline (1998-2000); and an Audit Examiner for Wachovia Corporation (1994-1996).  He received a B.A. in Economics from Ursinus College in 1994 and is a Certified Public Accountant. He is a member of the American and Pennsylvania Institute of Certified Public Accountants.

SHEILA A. MATHIAS, PhD, JD, MBA2022-01-17T14:31:29-05:00
Mathias headshot

Chief Scientific Officer

Dr. Sheila A. Mathias has more than 20 years of leadership experience in the pharmaceutical  industry accelerating drug development. She brings extensive global regulatory affairs strategic guidance and clinical development experience having worked across a range of  therapeutic areas, including pain management, addiction medicine, and dermatology. This experience has spanned across big pharma, mid-sized, to start-up biotechnology companies. Most recently, she held the position Senior Director Global Regulatory Affairs at Sun Pharma Advanced Research Company. Sheila has held increasing roles of responsibilities, entering the pharmaceutical industry at Merck US Human Health in the position of Medical Science Liaison. Dr. Mathias transitioned into Regulatory Affairs at Aventis Pharmaceuticals and has successfully  brought multiple products through regulatory approval.  Dr. Mathias received a B.S in Zoology from Howard University, a PhD in Neurophysiology from Meharry Medical College, an executive  MBA from Saint Joseph’s University, and  a JD from Northwestern California University School of Law.  Since 2018 she has served on the Advisory Board for Tennessee State University Department of Biology.

100+ YEARS

OF COMBINED EXECUTIVE EXPERIENCE IN THE PHARMACEUTICAL INDUSTRY

SubheadBOARD MEMBERS
ANTHONY P. MACK, MBA2022-05-23T19:37:04-04:00
Mack headshot

Chairman + CEO

Anthony P. Mack is an entrepreneur who has founded three successful pharmaceutical companies, served on executive boards and has more than 35 years of experience in the industry including 10 years in finance. Prior to founding and taking Virpax Pharmaceuticals public (Nasdaq: VRPX), Mr. Mack founded Scilex Pharmaceuticals and served as President, CEO and Director until February 2018. Scilex was sold to a publicly traded company. Mr. Mack founded his first pharmaceutical company, ProSolus Pharmaceuticals, in 2009 where he served as President and Director before selling the company to Mission Pharmacal in 2015. As a key executive in the pharmaceutical industry, Mr. Mack has overseen global strategies to advance business development, product development, market research, regulatory positioning, marketing and commercialization. Prior to his pharmaceutical career, Mr. Mack worked in the financial sector, starting as a Series 7 broker dealer then a Series 24 licensed Principal, allowing him to supervise and manage brokers at affiliated branches. Mr. Mack holds an Executive MBA in Pharmaceutical and Healthcare Marketing from Saint Joseph’s University.

JEFFREY GUDIN, MD2021-04-21T19:00:49-04:00

EVP, Chief Medical Officer

Jeffrey Gudin, MD, is co-founder and Executive Vice President at Virpax. Dr. Gudin completed both an anesthesiology residency and pain management fellowship at Yale University School of Medicine, and has been active in the pain management space as a clinician, consultant and researcher for more than 25 years. He is  Board Certified in Pain Medicine, Anesthesiology, Addiction Medicine and Hospice and Palliative Medicine. Dr. Gudin is on faculty at the University of Miami Miller School of Medicine in the Department of Anesthesiology, Perioperative Medicine and Pain Management. He has assisted in the development and marketing of numerous analgesics, and is currently principal investigator on an analgesic project awarded a grant through the National Center for Advancement of Translational Sciences at the NIH. He has presented at numerous national and international pain congresses, and has dedicated his career towards risk management and the development of safer, more effective pain medications.

GERALD W. BRUCE2021-07-30T14:06:38-04:00

Gerald W. Bruce has spent over 30 years, including 20 years in senior leadership roles, in the Pharmaceutical and Medical Nutrition industry. He started his career at Johnson and Johnson where he was an award-winning sales representative and held leadership positions of increasing responsibility in sales and marketing ending with his role as Group Product Director of Analgesics. He then served as Vice President of Sales at Bristol-Myers Squibb where he led the Cardiovascular and Metabolic sales force responsible for over $1.2 Billion in sales. He later served as Vice President of Managed Markets where he led the team responsible for the development and implementation of the reimbursement strategy for the Bristol-Myers Squibb $7 billion US portfolio. Mr. Bruce went on to become the Senior Vice President of Commercial Operations at NitroMed where he was responsible for building the commercial strategy and led the team responsible for the development and implementation of the commercial plan for the start-up company’s first product for the treatment of Heart Failure. He also spent close to ten years in the Medical Nutrition industry where he was Vice President of Sales for Nutricia North America, Danone Medical Nutrition Division. Mr. Bruce currently serves as Chairman of the Board of Trustees for Lincoln University and serves on the executive committee of the Board for the National Sales Network. He received his bachelor’s degree in Business Administration from Lincoln University and a master’s degree in Leadership from the McDonough School of Business at Georgetown University.

ERIC FLOYD, PhD2021-04-21T18:55:30-04:00

Dr. Eric Floyd serves as the Principal and CEO at Floyd Regulatory Strategic Consulting. In this role, he works to successfully propel operational growth (P&L) and drug development for pharmaceutical companies. Prior to his current role, Dr. Floyd  previously served as the Chief Regulatory Officer at Neurogene, the Senior Vice President of Global Regulatory Affairs at Axovant Sciences, the President of  Compliance Services and the Chief Scientific Officer at Dohmen Life Science  Services, and as the Vice President of Regulatory Affairs and Quality Assurance at  Lundbeck. Dr. Floyd received his B.S. from University of Illinois Urbana-Champaign, his M.Sc. in Neuroscience from Tennessee State University, his Ph.D. in Neurophysiology from Meharry Medical College, his Executive M.B.A. from Saint  Joseph’s University, and an International M.B.A. from INSEAD.

JERROLD SENDROW, CFP2022-03-21T22:04:37-04:00
Jerry Sendrow headshot

Mr. Jerrold Sendrow has been a Certified Financial Planner since 1986, and maintains an active practice. Mr. Sendrow also served as an outside Director on the Board of Directors of SCILEX Pharmaceuticals Inc. from 2014 to 2016. In addition, up through 2014, Mr. Sendrow has more than 35 years of experience as Chief Financial Officer and Director in companies with revenues in excess of $500 million. Jerry has led these companies through start-up, survival, turnaround and growth modes. Prior to that, Mr. Sendrow was an accountant in the audit departments of Touche Ross & Co. and Peat Marwick Mitchell & Co after returning from military service of two tours in the Vietnam conflict. Mr. Sendrow holds business degrees from Bernard Baruch College of the City University of New York and Adelphi University.

THANI JAMBULINGAM, PhD2022-03-17T09:50:38-04:00
Thani Jambulingam headshot

Dr. Thani Jambulingam is a Pfizer Fellow and Professor in the Department of Pharmaceutical and Healthcare Marketing at St Joseph’s University, Erivan K. Haub School of Business, in Philadelphia, Pennsylvania, USA. He teaches in the executive MBA program for biopharmaceutical, medical device and physician executives. Dr. Jambulingam served as the chair of the department for 8 years. He is trained at Harvard in case method for teaching. Dr. Jambulingam’s research interests are in pharmaceutical and healthcare strategy, and innovation and published in marketing and management journals. Dr. Jambulingam has also served as a consultant and facilitated training sessions in innovation and strategy for senior leadership and/or brand teams within several small, mid and large pharma and healthcare firms including Alkermes, Abbott, Astra Zeneca, Lancaster General, Merck, Novo Nordisk, Pfizer, Solvay and Procter & Gamble. During his sabbatical, he joined Pfizer with the Prevenar Global Commercial Team contributing to development of Prevenar franchise positioning, healthy aging platform development, vaccine business strategy for emerging markets, pediatric expanded age strategy (life cycle management) and conducted strategy session for executive leadership within the specialty care division of Pfizer. Dr. Jambulingam is a pharmacist and obtained his Ph.D. from University of Wisconsin-Madison.

VANILA M. SINGH, MD, MACM2021-04-21T18:52:18-04:00

Director

Dr. Singh was the immediate past Chief Medical Officer in the US Department of Health and Human Services (“HHS”).  She served as the Chairperson of the highly regarded HHS Task Force in conjunction with the Department of Defense and the Veterans Administration. Dr. Singh is a clinical associate professor of Anesthesiology, Pain and Peri-operative Medicine at Stanford and is a teaching mentor at Walter Reed National Military Medical Center. She served in medical ethics as well as on scientific editorial boards, committees for the American Society of Regional Anesthesia, American Society of Interventional Pain Physicians, California Medical Association, and the Santa Clara County Medical Association. Dr. Singh, who is double board-certified in pain and anesthesiology, focuses her practice on regional anesthesia and peri-operative, subacute, and the development of chronic pain, with an appreciation for complimentary and traditional medicine approaches that emphasize an individualized patient-centered approach. She completed a masters in academic medicine as part of her professional development to further enhance leadership, educational curriculum development, and interdisciplinary work. Dr. Singh received her medical degree from George Washington University Medical School and her B.A. from U.C. Berkeley in Cell Biology/Economics.

MICHAEL F. DUBIN, CPA2021-11-19T15:49:33-05:00

Director

Michael Dubin is an accomplished senior executive, Certified Public Accountant, independent consultant, advisor, and thought leader with 40 years of experience and success in manufacturing, distribution, financial services, business and professional services, pharma, technology, retail and various other industries. His areas of expertise and experience also include leading executive teams, executive leadership training, operations management, profit optimization, board governance, financial reporting, and other financial management matters. Previously, Mr. Dubin held the title of Managing Partner, PA/SNJ Offices, with RSMUS LLP (RSM), a $2.8B professional services company with over 12,000 employees. He was presented with RSM’s “National Achievement Award” in 2010, and was a finalist for the company’s “National Integrity Award.” Mr. Dubin obtained a BS in Economics (magna cum laude) from the Wharton School of Business, University of Pennsylvania. He served as a Board Member for RSM for four year and is also a board member and the Audit Committee Chairman for a privately held business in Philadelphia engaged in supplying energy efficiency services and facilities, and a board member and the Risk Management Committee Chairman for a commercial bank in Pennsylvania. Mr. Dubin is professionally affiliated with the PICPA and AICPA. He was also an adjunct faculty member and course teacher for the Wharton School of Business for two years and has also been a guest lecturer, at the Wharton School-University of Pennsylvania, Temple University, University of Scranton and Lehigh University. He also served as an expert witness/consultant for the Federal Deposit Insurance Corporation (FDIC) and the Resolution Trust Corporation (RTC).

Our experienced executive team and board have

PROVEN TRACK RECORDS

developing, launching, and marketing numerous FDA approved products

SubheadOUR PARTNERS
NIH Logo

National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS)

Virpax advances Envelta™ Development with NCATS Under CRADA Agreement to support the development and manufacturing of Envelta. The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) has awarded research and development contracts to support Good Manufacturing Practices (GMP) production of drug substance and drug product. as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies to develop Envelta.

Envelta is Virpax’s endogenous enkephalin intranasal spray for Acute pain, including pain associated with cancer. Virpax entered into a Cooperative Research and Development Agreement (CRADA) with NCATS on August of 2020.

usaisr logo

The U.S. Army Institute of Surgical Research (USAISR)

Virpax entered into a cooperative research and development agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) on May 5, 2022 to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine in a hydrogel formulation that is injected at the wound site. Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications.  In pre-clinical trials, Probudur has shown pain control for 96 hours. The USAISR is the U.S. Department of Defense’s (DOD) primary laboratory for developing solutions for trauma and critical care challenges in combat casualties.

LEARN HOW YOU CAN MAKE A DIFFERENCE

LEARN MORE
Go to Top